Musi wa29 Ndira, 2025, chikwata chekutsvagisa chekuChina chakaburitsa chinyorwa chine musoro unoti “Neoadjuvant pyrotinib uye trastuzumab mukenza yemazamu yeHER2 positive isina mhinduro yekutanga (NeoPaTHer): kushanda zvakanaka, kuchengetedzeka, uye kuongororwa kwebiomarker kwechidzidzo chakagadziriswa mhinduro, chakavakirwa pamapoka akawanda” mujenari rekuti “Signal Transduction and Targeted Therapy”.
Kenza yemazamu yemunhu inonzi human epidermal growth factor receptor 2 (HER2), iyo inoumba ~15% kusvika 25% yekenza dzese dzemazamu, inozivikanwa semhando yakasiyana uye ine hukasha. Inoratidzwa nekuwanda kweHER2, transmembrane receptor tyrosine kinase inokurudzira kuwanda kwemasero ekenza uye kurarama. Varwere vane HER2-positive cancer vanotarisana nenjodzi yakakura yekudzoka uye kufa kana tichienzanisa nevaya vane dzimwe mhando dzekenza yemazamu, zvichiita kuti ive chirwere chakaoma kurapa. Zvisinei, mamiriro ekurapwa kweHER2-positive cancer kenza yemazamu akachinja zvinoshamisa mumakumi maviri emakore apfuura, kunyanya nekuda kwekuunzwa kwemishonga inotarirwa neHER2. Kunyanya, kuuya kwetrastuzumab kwakachinja zvakanyanya nzira yekenza yemazamu yeHER2-positive kubva pachirwere chinouraya zvikuru kuenda kune chine mhedzisiro iri nyore uye isina kuipa.
Pakati paGumiguru 2020 naKurume 2022, varwere vanosvika zana nemakumi maviri nevapfumbamwe vanobva kuzvipatara zvishanu vakanyoreswa muchidzidzo ichi. Pavarwere zana nemakumi maviri nevapfumbamwe vakanyoreswa, makumi matanhatu nevaviri (48.1%) vakaonekwa sevaya vanopindura MRI (boka A), makumi maviri nevatanhatu vasina kupindura vakaramba vachiongororwazve neTCbH (boka B), uye makumi mana nerimwe vasina kupindura vakapihwa imwe pyrotinib (boka C). Mwero we tpCR waive 30.6% (95% CI: 20.6–43.0%) mu cohort A, 15.4% (95% CI: 6.2–33.5%) mu cohort B, uye 29.3% (95% CI: 17.6–44.5%) mu cohort C. Kuongororwa kwe logistic regression kwakaratidza mikana yakafanana yekuwana tpCR pakati pe cohorts A ne C (mikana = 1.04, 95% CI: 0.40–2.70). Hapana zviitiko zvitsva zvakaipa zvakaonekwa nekuwedzera pyrotinib. Varwere vane co-mutations ye TP53 ne PIK3CA vakaratidza mwero wakaderera wemhinduro yekutanga yechikamu zvichienzaniswa nevaya vasina kana vane rimwe gene mutation (36.0% vs. 60.0%, P = 0.08). Zvakawanikwa izvi zvinoratidza kuti kuwedzera pyrotinib kunogona kubatsira varwere vasingapindure neoadjuvant trastuzumab pamwe ne chemotherapy. Ongororo yakawedzerwa inofanirwa kuitwa kuti paonekwe zviratidzo zvebiomarker zvinofanotaura kubatsirwa kwevarwere nekuwedzera pyrotinib.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Mareferensi
https://www.nature.com/articles/s41392-025-02138-6
Nguva yekutumira: Kukadzi-08-2025